产品
编 号：F536716
分子式：C19H12F6N4O2
分子量：442.31
分子式：C19H12F6N4O2
分子量：442.31
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 952565-91-2
产品详情
生物活性：
ASP-4058 is a next-generation, selective and oral bioactive agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P1 and S1P5), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.
体内研究：
ASP4058 (p.o., daily for 21 days) reduces the clinical score in a dose-dependent manner and the cumulative clinical score from day 0 to 21 dpi at 0.03, 0.1 and 0.3 mg/kg are 15.5±1.48, 9.50±2.17 and 1.17±1.17, respectively, while that of vehicle-treated group is 15.5±0.619 in rats. ASP4058 prevents decreases in body weight of EAE rats.ASP4058(p.o., daily for day 12 to day 45) maintains the clinical score at a relatively low level and the cumulative clinical scores (18-45 dpi) among the groups treated with 0.1 and 0.3 mg/kg dosages are 6.90±2.85 and 5.60±2.21, respectively in mice. The ED50 values for ASP4058 is 0.063 mg/kg.Animal Model:Male Lewis rats with an induction of EAE.
Dosage:0.03, 0.1 or 0.3 mg/kg.
Administration:Oral administration once daily for 21 days.
Result:Reduced the clinical score in a dose-dependent manner and the cumulative clinical score.
Animal Model:SJL mice immunized with PLP139-151 and boosted with pertussis toxin developed relapsing-remitting EAE.
Dosage:0.1 and 0.3 mg/kg
Administration:Oral administration once daily from day 12 to day 45.
Result:Maintained the clinical score at a relatively low level and the cumulative clinical scores (18-45 dpi).
ASP-4058 is a next-generation, selective and oral bioactive agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P1 and S1P5), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.
体内研究：
ASP4058 (p.o., daily for 21 days) reduces the clinical score in a dose-dependent manner and the cumulative clinical score from day 0 to 21 dpi at 0.03, 0.1 and 0.3 mg/kg are 15.5±1.48, 9.50±2.17 and 1.17±1.17, respectively, while that of vehicle-treated group is 15.5±0.619 in rats. ASP4058 prevents decreases in body weight of EAE rats.ASP4058(p.o., daily for day 12 to day 45) maintains the clinical score at a relatively low level and the cumulative clinical scores (18-45 dpi) among the groups treated with 0.1 and 0.3 mg/kg dosages are 6.90±2.85 and 5.60±2.21, respectively in mice. The ED50 values for ASP4058 is 0.063 mg/kg.Animal Model:Male Lewis rats with an induction of EAE.
Dosage:0.03, 0.1 or 0.3 mg/kg.
Administration:Oral administration once daily for 21 days.
Result:Reduced the clinical score in a dose-dependent manner and the cumulative clinical score.
Animal Model:SJL mice immunized with PLP139-151 and boosted with pertussis toxin developed relapsing-remitting EAE.
Dosage:0.1 and 0.3 mg/kg
Administration:Oral administration once daily from day 12 to day 45.
Result:Maintained the clinical score at a relatively low level and the cumulative clinical scores (18-45 dpi).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备